Free Trial
NASDAQ:EWTX

Edgewise Therapeutics (EWTX) Stock Price, News & Analysis

Edgewise Therapeutics logo
$32.20 +0.22 (+0.69%)
(As of 11/22/2024 ET)

About Edgewise Therapeutics Stock (NASDAQ:EWTX)

Key Stats

Today's Range
$31.76
$32.72
50-Day Range
$16.86
$36.62
52-Week Range
$5.93
$38.12
Volume
353,056 shs
Average Volume
695,699 shs
Market Capitalization
$3.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.50
Consensus Rating
Buy

Company Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Edgewise Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
54th Percentile Overall Score

EWTX MarketRank™: 

Edgewise Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 541st out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Edgewise Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Edgewise Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Edgewise Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Edgewise Therapeutics are expected to decrease in the coming year, from ($1.46) to ($1.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Edgewise Therapeutics is -21.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Edgewise Therapeutics is -21.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Edgewise Therapeutics has a P/B Ratio of 6.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Edgewise Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    12.19% of the float of Edgewise Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Edgewise Therapeutics has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Edgewise Therapeutics has recently decreased by 14.13%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Edgewise Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Edgewise Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.19% of the float of Edgewise Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Edgewise Therapeutics has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Edgewise Therapeutics has recently decreased by 14.13%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Edgewise Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Edgewise Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 3 people have searched for EWTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Edgewise Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,893,316.00 in company stock.

  • Percentage Held by Insiders

    24.11% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Edgewise Therapeutics' insider trading history.
Receive EWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EWTX Stock News Headlines

Edgewise Therapeutics initiated with an Outperform at Evercore ISI
Ever heard of this 8-day bitcoin profit window?
Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.
Edgewise Therapeutics (EWTX) Receives a Buy from Evercore ISI
FY2024 Earnings Forecast for EWTX Issued By Leerink Partnrs
See More Headlines

EWTX Stock Analysis - Frequently Asked Questions

Edgewise Therapeutics' stock was trading at $10.94 at the beginning of the year. Since then, EWTX stock has increased by 194.3% and is now trading at $32.20.
View the best growth stocks for 2024 here
.

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.01.

Edgewise Therapeutics (EWTX) raised $150 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO.

Edgewise Therapeutics' top institutional investors include Novo Holdings A S (5.94%), Janus Henderson Group PLC (4.81%), Frazier Life Sciences Management L.P. (2.99%) and Braidwell LP (2.07%). Insiders that own company stock include Peter A Thompson, Orbimed Advisors Llc, Holdings A/S Novo, Joanne M Donovan, Kevin Koch, Behrad Derakhshan, Alan J Russell, Jonathan C Fox, R Michael Carruthers and John R Moore.
View institutional ownership trends
.

Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Edgewise Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and First Solar (FSLR).

Company Calendar

Last Earnings
11/07/2024
Today
11/23/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/27/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EWTX
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.50
High Stock Price Target
$51.00
Low Stock Price Target
$31.00
Potential Upside/Downside
+22.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-100,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.16 per share

Miscellaneous

Free Float
71,859,000
Market Cap
$3.05 billion
Optionable
Optionable
Beta
0.14
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:EWTX) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners